Search

AI infrastructure spending will keep supporting Big Tech valuations while yen volatility stays a policy headache.

This is the cleanest cross-asset signal in the finance feed: AI spending is still being rewarded, but macro risk has not gone away.

Horace Mann’s valuation debate will likely intensify if investors keep treating raised guidance as proof the stock deserves a premium.

This is a clean example of a stock where guidance and valuation are colliding. It may not be the biggest story, but it is a useful market read-through on pricing optimism.

IQVIA will likely use the Medera partnership to deepen its advanced-R&D pitch, while investors watch whether guidance gains convert into earnings.

This is a useful signal on where large clinical-services players are trying to grow: AI, real-world evidence and next-generation therapies. Investors will watch whether the narrative translates into margin expansion.

Rocket’s integration story will stay in focus as investors test whether Mr. Cooper and Redfin synergies can sustain profitability.

The market will judge whether the rebound is cyclical or structural. If the synergy story holds, Rocket’s margin profile could keep improving even in a tough housing market.